>PROKKA_00001 Clostridium P-47 protein
MQTTTLNWDTVYAVPINIVNEAIKLKHPTPENFELLNGKYGNCSGSFEEWQITNGGDGSN
IRLKIPIKNFKATIIGNRLNGKGGFAFANLEVQVKLKYLPHFPQSKNKDIELVDLKIRTQ
SDNPEDPAIIVISSYKNIQGFYFEDEYKLTEDDEFVVSYFYRLIKEWLEKNLHFFNYIFN
TVNLNLYISDKEKWEWTKPSYVDYAYSEIEGDLSKSALGVLCMTGGRTGSKNQQQKIDPY
AIPKKSQSGFLISEERLLRNILLPTIPKKFPKSKGDEFEVINESSQGGGYSYILKLKKGK
KIDLENIQAVGYTCTPYIQEMKIYLLGSYLKLETTTRVDLPLGVASICETTCEYKFKLST
NNKGEQTIAYEQIGSPVNIQYSENTGNVGLNIVVSFLSATLSFALTFVPGFGTFLAVGLI
GGCLIGSVALIPTFIESYNSDTAPSIDLSLENSVSEITWNSSDVFNLDYVALAGPLQLGG
TLQVQNS*
>PROKKA_00002 Clostridium P-47 protein
MTNLKPYIIYDWKETILKNSKDNYSINESIPKIFSKKICGGRFFNSTLSGNWKSWTLTDE
GEGPHPVLKCTIDNGYLEIYSNTSSEKHSLKDIEIKVCMSIKPNSDGTHSLCKNSFYIKT
NSLKLSEDRLILSHCLDKLILAWFKDNHKYIELFINRSRIQTRVEGDLSLLGWDIESSVS
YKTMNEFIKKDNLYEKKFHQYMEVRRNEYTIDGEFGPWQMTTGADGQNIRFLCPIKSATY
KINDDVYIAKPDNFIIIQVDLKYFDSKTTIIDPSGLNNGQQLNLKVKTDSTDEINAVILV
GSRITDVNEDLYPGDDISLEIVFKTWFNTNIQKFTQIFSYILLNETSKIPEYQWLKPTQI
SYGSASVTMPDPSNPNKELSNLDASTFAAMAMVENHKNDRPNHAVDNRFLELSKTPAAFA
ISMPEFLKHFLVTGLQAMQIDNLDAFEVSSENLVITNKKKINFGKIQDQNRQVDALIEPN
NFKLAIQNNQVVVEIVDATWQQVVGVTGHFGYRQAYNLILKNENNVYKPMLEESGDVTIS
YMVTEEAWKTTQDAIISATVGLVVGTIIGTAFSKLSDKLYKFLKSKFIVKNKKASLKISG
KDINEVIEMSDLSKPQLLSIKKANAKISTEEVGLISQNGSTSLENLAIFKNKPRPIGERV
QILGLKLVSGLITTFGWSIGFVLPDILKDVINANINNNFEVLPGIQQFTQQCIGSIQWPD
NSELKIDFAKLQGVYLLGGNLVKIPESN*
>PROKKA_00003 hypothetical protein
MELKQAFVFEFDENLSSSSGSIHLEKVKQNCSPNYDYFKITFIDGYLYIKNKSGVILDKY
DLKNVISLVALKRDYLSLSLSNNKQIKKFKNIKNKHLKNKFNLYVINEDIEKRITKNGIL
EEVILNKMLLSILLGNEENLLQIS*
>PROKKA_00004 Clostridium P-47 protein
MNTYGWDIVYGCSNMVVNKHLKNYIDENRIEFLYSDINKKEEIKMIFDNWEIINGGTSNF
LRIKIFIKEGYFKFKNIIVDLSGVIPILEIKLDFFNDSSNPHIKELKFSFGNKTNDDIKV
IVSDLSGKLYEEDEFYFNNLLICAFINNEKQVSYIFASLNVKSNIAWMNPKQFKFVYYSP
TDNSDGYLCILSVVTNRDISKLSTNVDSSILSENSEVGLLISEKLFMENLVLPKLSSNMG
SNITSNNFNVINTSDTTGIIKNKNTLNWYGIKVAALYYYPEINDFSMELFEGNKLKTRLS
GIVKLTGYERIYSKLNMECITKFIYDNKNKKVSFEIYSTPIMECRPIFGLLDGIPAAVAK
SVGNWSLKSFRDSLAFELANNFTDIINDIVNWNNLKISEVTNIILNVGFCIQGNMN*
>PROKKA_00005 Botulinum neurotoxin type E precursor
MKINGNLNIDSPVDNKNVAIVRSRKSDVFFKAFQVAPNIWIAPERYYGESLNINEDQKSD
GGIYDSNFLSTNNEKDDFLQAIIKLLQRINNNVVGEKLLSLISTAIPFPYENNTEDYRQT
NYLSSKNNEHYYTANLVIFGPGSNIIKNNVIYYKKEYAESGMGTMLEIWFQPFLTHKYDE
FYVDPALELIKCLIKSLYYLYGIKPNDNLNIPYRLRNEFNSLEYSELDMIDFLISGGIDY
KLLNTNPYWFIDKYFIDTSKNFEKYKTDYEIKIKNNNYIANSIKLYLEQKFKINVKDIWE
LNLSYFSKEFQIMMPERYNNALNHYYRKEYYVIDYFKNYNINGFKNGQIKTKLPLSKYNK
EIINKPELIVNLINQNNTVLMKSNIYGDGLKGTVDNFYSNYIIPYNLNYEHSINYSYLDN
VNIEEIEKIPPINDEDIYPYRKNADTFIPVYNITKAKEINTTTPLPINYLQAQMIDSNDI
NLSSDFLKVISSKGSLVYSFLNNTMDYLEFIKYDKPIDTDKKYYKWLKAIFRNYSLDITE
TQEISNQFGDTKIIPWIGRALNILNTNNSFVEEFKNLGPISLINKKENITIPKIKIDEIP
SSMLNFSFKDLSENLFNIYCKNNFYLKKIYYNFLDQWWTQYYSQYFDLICMASKSVLAQE
KLIKKLIQKQLRYLMENSNISSTNLILINLTTTNTLRDISNQSQIAINNIDKFFNNAAMC
VFENNIYPKFTSFMEQCIKNINKSTKEFILKCTNINETEKSHLIMQNSFSNLDFDFLDIQ
NMKNLFNSYTELLIKEQTSPYELSLYAFQEQDNNVIGDTSGKNTLVEYPKDIGLVYGINN
NAIHLTGANQNIKFTNDYFENGLTNNFSIYFWLRNLNQNTIKSRLIGSKEDNCGWEIYFE
NDGLVFNIIDSNGNEKNIYLSNISNNSWHYIVISINRLKDQLLIFIDNILVANEDIKEIL
NIYSSDIISLLSDNNNVYIEGLSVLNKTINSNEILTDYFSDLNNSYIRNFDEEILQYNRR
YELFNYVFPEIAINKIEQNNNIYLSINNENSLNFKPLKFKLLNTNPNKQYVQKWDEVIFS
VLDGTEKYLDISTTNNRIQLVDNKNNAKIFIINNDIFISNCLTLTYNNVNVYLSIKNQDY
NWVICDLNHDIPKKSYLWILKNI*
>PROKKA_00006 Botulinum neurotoxin type E precursor
MPKINSFNYNDPVNDKTILYIKPGGCQQFYKSFNIMKNIWIIPERNVIGTIPQDFLPPTS
LKNGDSSYYDPNYLQSNEEKDRFLKIVTKIFNRINDNLSGGILLEELSKANPYLGNDNTP
NNQFHIGDASAVEIKFSNGSQSILLPTVIIMGAEPDLFETNSSNISLKNNYMPSNHGFGS
IAIVTFSPEYSFRFNDNSMNEFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQQQNPL
ITNIRGTNIEEFLTFGGTDLNIITNAQSNDIYTNLLDDYKKIASKLSQVQVSNPQLNPYK
DVFQEKYGLDKDANGIYSVNINKFNDIFKKLYSFTEFDLATKFQVKCRKTYIGHHKYFRL
SDLLNDSIYNISDGYNINTLKVNFRGQNTNLNTRIITPITGRGVVRKIIRFCTNIFSPKG
IRKSICIEVNNGELFFVASENSYNDDNINTSKEIDDTVTSNNNYENDLDQVILNFNSESA
PGLSDEKLNLTIQDDAYIPKYDSNGTSDIEQYDVSELNVFFYLDAQKVPEGENNVDFTSS
IDTALLEQPKIYTFFSSKFISNLNKTMQAALFVSWIQQVLVDFTTEATQKSTVDKIADIS
IVVPYIGLALNIGNEAQKGNFKDALELLGAGILLEFEPELLIPIILVFTIKSFLGSSDNK
NKVIKAINNALKERDENWKEVYSFIVSNWMTKINTQFNKRKEQMYQALQNQVNAIKTIIE
SKYNSYTLEEKNELKNKYDIEQIENELNQTVSIAMNNIEIFLTESSISYLMKLINEVKIN
KLKEYDENVKTYLLDYIIKHGSILGESQQELNSMVIDTLNNSIPFKLSSYTDDKILISYF
NKFFKTIKSSSVLNMRYKNDKYIDTSGYDSNINIKGDVFIYPTNKNQFGIYNNKLSEVNI
SQNDYIIYDNKYKNFSISFWVRIPNYDNKIVNVNNEYTIINCMRDNNSGWKVSLNHNEII
WTLQDNAGINQKLVFKYGNANGISDYINKWIFVTITNDRLGDSKLYINGNLIDKKSILNL
GNIHVSDNILFKIVNCSYTRYIGMRYFNIFDKELDKTEIETLYNNEPNTNILKDFWGNYL
LYDKEYYLLNVLKPNNVIDSNRDSTFSIHNIRSTIVLANRLYSGIKVKIQRVNNSSTNDN
LVRKNDQVYINFVASKTHLFPLYADTNTTNKEKTIKSSSSGNRFNQVVVMNSVGNNCTMN
FKNNNGNNIGMLGFKDNTLVASTWYYTHMRDNTNSNGCFWNFISEEHGWQEK*
>PROKKA_00007 Helix-turn-helix domain protein
MNRNIIGKKVRIIRKAKNLTQEELIVRIQLKGLNINRPMLSRIETDSREVYDFKVKAIAE
ALDISVDELFIQN*
>PROKKA_00008 Replication-associated recombination protein A
MTPLAERMRPTKLEDFVGQKQIIGEGKPLYNIIKSKNIVNCILYGPPGTGKTTLANIMAN
YVDRKFYKLNATTASVKDIQEIASSLDTLLGYNGVVVYIDELQHFSKKQQQSLLEFIEKG
QITLIASTTENPYFVLHKAILSRCNIFTFKPLTTDDIKFGVVKAIERAIENGMEIKYTDD
AISYIAEISQGDYRKAYNILELGIISSLKRTLEITVEYIEELEQSHIRFDASGDEFYNSL
SALQKSIRGSDADAAIHYLARLTKSGNLTAIVRRLGVIVAEDIGLAHPNALTVVNSGLEL
VLKVGLPEAQLILSELVIYLATLPKSNSAYLAIKSAMQDLENKNVGDVPVHLKDAHYSSA
QKLGVGGYKYPHDYSNNYVKQKYMPQELRDTIYYIPQENKYEGSIKNYWKNIKE*
>PROKKA_00009 hypothetical protein
MGKVGRKENCNISDNDMLVALERYTREFPNEKINIKKLADFSGIERHYWYSRKGFREKIE
EINSISYEKYDIISDGDRKKIKFPNVDEVVDNNFRNKKRLKFILNSFFLTYQDFYESSCE
AYKLKKDINILKDKIIKYEDEIQKLKNERDKFRELSNYNENKYYEIAIRSRERNFRKENN
IKSNVIEINNKNIKAYSTDEDDLDSLLNRIDD*
>PROKKA_00010 hypothetical protein
MNNKQQYKLALREGLLVNQIANNSDSLVIVTKELKIYKEEELDYYKEKFNYFKKKGRIVN
CVFNDLIWTLSETDEGGYKSNRNIKFSINFINKNNIIKAYLINLLINLININTIVERVRV
VSDIINISNFFDIDKFNEFEEYIESTFDNNKLNMKDYTMNFISFIRDNVDEEYCNYLVSL
PNEYFSKTREIPDYTSILKFDFLLDKYLKNSDEKEFFRYYPIVLWWKICSKIPLRPCEFM
ILKKDCVYEKNRKYYIRIRRCKPHGFVNKALNIRKEQSFRINKEIYDLVMKVVSHKSHDC
EFLLSKNLYNKYYTQYTYKEELVQGRVMRSYNLDKCLKDFYYYEINNKNIQTVISKKDVK
ESLSQQFYRDCMVSLQLGDARHLAIINLVLQGTNSYLIREMCGHRDINSHLHYIDHAKTY
ITSKVLVLTDIRKLEIKLANIYSNESFEYGNKRNNKVSNLLYNEYKKVGDIYCKRYVGRK
EMFPFLCLTDCDECNDKVETDFTGNTDEEIKTNKMEIERQFQIIEKYLKDAQFNSIIDSK
NERVLFESQKNIEESANKLNYLISKEAELEAKIFFGGMITKEE*
>PROKKA_00011 hypothetical protein
MNKENVVIELEDAAKEINPKCYKYFMKKLKTLNNINIFDKNGKLFITKNDFEKLKRNKAS
KIPYHIDIPNGYASRNEAVKKYNINYNSLRHNEEKGIIKTAISGGIAFLEKESIEKHIEF
LKYIEKINNDDNWIKVSSLRGKAYYDRISYTVRRNDFKNDLIKIGIGRTAEFFITRKLYK
EIINGKHKIIVTSQHKKKILKDDIEGIITKLLIETGVNSIRQKAKMKQLIKVKEISELSG
IDYEEIIESRRYFNGEIVKEQNIEYMHRYDIENIMKNFGYYSIKKLSKICGISFSTLIRD
FNIANFLGIYINFKIDKDFFVDINGVEIILKEFSKNYIATLTLDEIYRERMKLFPDEFFK
TYKLADEFIVKKKRNCYRPYGEDTTSYNRVINSIENLVNYLDKEIFEYSAEELLKLVSNT
NIVKRGYQAHVCQFINYVKRKMRNDCEYNKVFGLTLLTQYKIEKGENYLEKIYDKETWSK
YYVLLKDIDKHIVNAIKDPRYAQSWLYCILNLSVTWRKKNIILSLPRIKLQEIGVYEFEW
FSSKNVFTYSMAELVLNQIKFSLDGVIAYKNRRHLHINIPMSLKIPTAIAFIICEIHCRE
KSKDNIMYELAQSYIRKSDYKKLFEDDKLLNFENLKCTRSIISYGFSHAINTIGTVPAAY
KIYSNRRSHSDSEQKITNVTGDHYIALDGIENGAKEFMFHVVERGAFGFMYYKLFKCFFD
KKDFENISQEQLTDLTKYSDQILNPRTLENIADKFIENDRINKLSIFEILWYSSIIKNKG
KRDLSSKSNIFLAIMIDLYKKQSEDLLGKSDEFKTFVDEKYLQLDAEIEDILKNKISTSK
IIDNILNGSNCCYSKDTNCIFDRIERKELCPYKYEDNGGKSCVGCKYNLLTVYALNEINE
KMQTLLDKIQKKSYFTKEEIQKNSYILKNYVSIILEASVHFKNEEFLSNYINLKMIKTKI
YKLKSEGKIINI*
>PROKKA_00012 hypothetical protein
VFIISNIIDLRNTNSKYRFKVKVCKYKREGRYEDHLFQKAIIVLFDNITGKSRVHEFTEF
AIREFGKNRIKTQVDYLGKLVKFLNYVIKNKVKKNFKYLDFYDVEEFLQEIALDVQLNTF
NIYKMVLSRFYRYLAQKEWLINVSINDFIIKESEKNGGVMINYDIPICNIDIPDNIYRRN
THVMEYELQAMLLEVAIEEVNIIALAIFFQMFGGLRSGEIVNLTHSAVQCIGPYGRYGML
LDITDRNLRLDLKNNQAKGYSKKSRKQKVISPFNMLEKIYIQHMKKYKCVDDSGAIFVNK
DGMPMTIGSYNYYFDKLKKIFLKRLKESDNPTLKVQGDILCAAKWKTHIGRGIFSNNLGE
FMSASELKIARGDKYINSSDSYIEETKKIGKLYEENAEGAFQLLIKKINE*
>PROKKA_00013 Replication-associated recombination protein A
MSPLADLMRPSKIEDFVGQRHILGKNTPLYNLIKSKKICNCIFYGPPGTGKTTLANIMAK
YVDKKFYKLNATTASVKDIQNITSELDNLLNYAGVVLYIDELC*
>PROKKA_00014 molybdenum cofactor biosynthesis protein MoaC/MOSC-domain-containing protein
MGECIMPTNGVFAKVIEGGQMKIGDEIEIASGIEKMY*
